Sanofi Pasteur announced that the Food and Drug Administration (FDA) has approved the use of Menactra (meningococal [Groups A, C, Y, W-135] polysaccharide diphtheria toxoid conjugate vaccine) for booster vaccination against meningococcal disease in patients aged 15–55 years.
The new approval for Menactra was based on results of an open-label trial that studied the safety and immunogenicity of a booster dose among patient who received Menactra 4–6 years earlier.
Menactra was approved in January 2005 as the fist quadrivalent conjugate vaccine in the United States for active immunization against meningococcal disease caused by the serogroups A, C, Y, W-135. It is currently approved for vaccination in patients 9 months–55 years old.
For more information visit SanofiPasteur.US.